Immunotherapeutics Combining a Recombinant Chimeric Protein, Monophosphoryl Lipid A, and Miltefosine Against Visceral Leishmaniasis

Current treatment for visceral leishmaniasis (VL) is associated with toxicity, a high cost, and the emergence of drug-resistant parasite strains. Moreover, no human vaccine is available. In this context, immunotherapeutics combining vaccination and chemotherapy have emerged as a promising alternativ...

詳細記述

書誌詳細

主要な著者:	Marcelo M. Jesus, Daniela P. Lage, Breno L. Pimenta, Gabriel J. L. Moreira, Isabela A. G. Pereira, Raquel S. B. Câmara, Ana L. Silva, Grasiele S. V. Tavares, Karolina O. M. Falcão, Saulo S. G. Dias, Dóris M. Abrão, Maíza M. Rodrigues, João A. Oliveira-da-Silva, Mário S. Giusta, Miguel A. Chávez-Fumagalli, Bruno M. Roatt, Alexsandro S. Galdino, Myron Christodoulides, Camila S. Freitas, Eduardo A. F. Coelho
フォーマット:	Artigo
言語:	Inglês
出版事項:	MDPI AG 2025-11-01
シリーズ:	Pathogens
主題:	immunochemotherapy visceral leishmaniasis chimeric protein monophosphoryl lipid-A miltefosine immune response
オンライン･アクセス:	https://www.mdpi.com/2076-0817/14/12/1202
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!